Clinical TrialsSkye completed enrollment in the Phase IIa CBeyond trial of nimacimab with 136 patients, exceeding the target of 120 patients.
Competitive PositioningSkye’s nimacimab is in pole position in the CB1 inhibitor pipeline following Novo Nordisk’s Phase 2 data.
Partnerships And CollaborationsThe collaboration with Arecor Therapeutics could enable testing higher doses of nimacimab, potentially allowing for once-monthly dosing during future clinical development.